Background: Limitations of neutralization by single antigens and data bottlenecks in parasitic vaccine R&D Toxoplasma gondii, an intracellular parasite that infects more than one‑third of humans and warm‑blooded animals, represents a public‑health blind spot because it can cause fatal multi‑organ failure in immunocompromised individuals. Current single‑epitope vaccine guidelines fail to comprehensively control the parasite’s complex intracellular invasion and multi‑stage developmental kinetics, resulting in an inability to achieve protective tissue‑resident concentrations. Reliance on single‑antigen targeting without computational control of the parasite’s multifactorial immune‑evasion mechanisms leads to low protective efficacy and vaccine dropout noise, constituting a long‑standing barrier and data bottleneck to maintaining reversible systemic homeostatic protection.

Discovery: T‑SGR triple‑antigen mRNA‑LNP encapsulation and demonstration of protective efficacy in mouse cohorts State‑of‑the‑art research deployed a chimeric antigen—T‑SGR mRNA‑LNP platform—that fuses the parasite surface protein SAG1, the dense granule protein GRA7, and the rhoptry protein ROP16 to neutralize the multi‑stage infection barrier. The team pre‑computed secondary‑structure entropy changes of the in‑vitro‑synthesized transcript in silico and precisely assembled the multiplexed nucleic‑acid cassette using a lipid‑nanoparticle manufacturing process. Consequently, the optimized mRNA formulation outperformed both control groups and prokaryote‑derived recombinant protein vaccines, preserving innate immune sensor docking integrity and demonstrating non‑linear scaling of survival curves against highly virulent RH and moderately virulent ME49 strains, thereby confirming in‑vivo functional integrity.

Induction of Th1‑biased cytokine flux and directed lymphocyte proliferation kinetics Activation of the established multiplexed nucleic‑acid delivery matrix yielded synchronized humoral and cellular immune responses that fully overcame the saturation limits of conventional protein‑based vaccines. With 100 % N1‑methyl‑pseudouridine (m1Ψ) substitution and synchronized T‑SGR mRNA administration, IgG2a titers—characterized by superior neutralizing capacity relative to IgG1—were maximized, suppressing false‑positive prognostic noise below baseline levels. Simultaneously, splenic cell proliferation rate constants were elevated, and the per‑unit‑time secretion rates of IFN‑γ, IL‑12, and IL‑2 were non‑linearly amplified, establishing a high‑resolution immunological backbone capable of eradicating the parasite lineage.

Outlook: Establishing programmable parasitic‑medicine standards and activating next‑generation multi‑epitope IND governance This formulation‑pharmacology and computational‑immunology integrated data white paper resets vaccine governance from a static antigen‑locking paradigm to a programmable nucleic‑acid engineering infrastructure that computationally orchestrates parasite‑life‑cycle‑specific developmental tensors, enabling pin‑point design of composite epitopes. Future application of humanized microbiome models and commercialization will link culture‑condition‑specific translation efficiency weighting factors as correction coefficients, thereby eliminating batch‑to‑batch kinetic variability through a fully realized computational moat. The established T‑SGR receptor‑binding free‑energy constant will serve as a master asset for multinational pharmaceutical companies to meet the quantitative specifications of next‑generation digital‑health companion‑diagnostic platforms, and will function as backbone infrastructure that dramatically shortens global clinical‑trial protocol approval timelines.